IDO1 and pancreatic neoplasm: Upon sono-activation, the SPNNRH nanostimulants produce 1O2, which not only facilitates SDT of deep-seated pancreatic tumors and induces ICD in tumor cells but also triggers the controlled release of R848 and NLG919, thereby activating DCs and inhibiting IDO.